TG Therapeutics will showcase new BRIUMVI (ublituximab-xiiy) data at AAN 2026 in Chicago, including the first Phase 4 real-world observational analysis from the ENABLE study in patients initiating therapy and an update on the safety and tolerability of a modified dosing regimen from the ENHANCE study. Together, these readouts move the narrative beyond registrational efficacy to the practicalities of use in routine care, positioning BRIUMVI within the highly competitive anti-CD20 landscape for relapsing forms of multiple sclerosis.
The editorial question is whether pragmatic, real-world and dosing-optimization data can materially shift share in a class now defined less by headline relapse-rate reductions and more by operational friction, total cost of care, and site-of-care preference. BRIUMVI’s glycoengineered profile and streamlined infusion schedule have been central to its differentiation. ENABLE and ENHANCE give TG Therapeutics the opportunity to quantify that differentiation where it matters: in community infusion centers, across heterogeneous patient profiles, and under payer utilization controls that guide first- and second-line choices.
This matters now because decision-makers are recalibrating what constitutes value in MS. For patients, shorter chair time and predictable tolerability can reduce treatment burden and missed work, but confidence hinges on consistent post-marketing safety signals across settings, not just in academic centers. For neurologists and infusion providers, dosing regimens that minimize reactions without compromising depletion kinetics affect clinic throughput, staffing, and premedication workflows—determinants that can silently tilt product preference. For payers, the availability of real-world outcomes and detailed infusion resource use informs step therapy design, site-of-care policies, and contracting that weighs drug acquisition cost against administration time and avoidable adverse events. If ENABLE demonstrates stable effectiveness and manageable infection rates in broader practice, and ENHANCE supports efficient protocols, health plans will have a clearer rationale to approve initiation or switching, particularly where BRIUMVI’s price positioning offers budget impact advantages.
Competitively, this is a directed challenge to entrenched anti-CD20 therapies. The class has consolidated its hold on RMS as BTK inhibitor programs encountered clinical and regulatory turbulence, heightening the importance of within-class differentiation. Ocrelizumab remains the IV benchmark on efficacy breadth and brand familiarity, and ofatumumab offers home administration as a potent convenience play. TG Therapeutics is carving out a middle path that bets on infusion-center economics and operational simplicity as levers strong enough to overcome inertia and prior-authorization hurdles. The strategy reflects a broader industry shift: in crowded chronic markets, post-approval RWE and dose-optimization studies have become front-line commercial tools, not back-end scientific nice-to-haves. They influence care pathways, bolster medical education, and supply evidence packages that market access leaders can translate into policy wins.
The next test is scale and durability. Can TG Therapeutics convert ENABLE and ENHANCE into measurable policy changes, faster time-to-therapy, and higher persistence, before the next wave of competition—whether biosimilar pressure on class peers, renewed BTK momentum, or neuroprotective entrants—reshapes the battlefield again? Senior Commercial and Medical Affairs teams across neurology should watch whether these data drive payer updates, infusion-center uptake, and switching behavior over the next two contracting cycles, because that will signal how far pragmatic evidence can move markets when efficacy is no longer the differentiator.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
